An FDA advisory committee is meeting today to review MDMA-assisted psychotherapy to treat PTSD. Follow STAT's live blog throughout the day for updates.
tl;dr: the methodology was a major issue. Some critiques include that participants knew what they got (not because they were told but because getting high on MDMA is kinda obvious), which calls into question the placebo effect
Well, sounds like the FDA isn't the issue here then and they're just doing their jobs. Pretty short-sighted of the researchers to cut corners and possibly torpedo potentially effective treatment being approved for even longer.